|
Toward A Rational, Value-Based Drug Benefit For Medicare
Ruth Lopert and
Marilyn Moon
A major challenge facing Congress is what changes, if any, to make to Medicare Part D. With the apparent failure of the Democrats’ attempt to remove the prohibition on government intervention in drug price negotiations, the party’s next steps are unclear. One suggested option is a plan administered by the Centers for Medicare and Medicaid Services (CMS), to compete with private plans and facilitate a transition to a more rational structure. We discuss issues surrounding the design of such a mechanism and how it might provide a transition toward a more rational and sustainable drug benefit in the longer term.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
K. Outterson and A. S. Kesselheim
How Medicare Could Get Better Prices On Prescription Drugs
Health Aff.,
September 1, 2009;
28(5):
w832 - w841.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Moon
Improve Treatment Of Dual Eligibles
Health Aff.,
May 1, 2008;
27(3):
894 - 894.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Stuart
Where Are the Medicare Part D Claims Data?
Ann Intern Med,
February 5, 2008;
148(3):
239 - 240.
[Full Text]
[PDF]
|
|
|
|
